Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $2.49B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: FIVN stock price vs CTMX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CTMX's multiple
Needs CTMX P/E.
Implied fair value · at FIVN's multiple
Needs EPS (TTM) is negative, FIVN P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: FIVN FY 2025 (ended Dec 31, 2025) · CTMX FY 2025 (ended Dec 31, 2025).
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 75% equity / 25% debt · EV / Revenue 2.66x · EV / EBITDA 22.40x
Capital structure 98% equity / 2% debt · EV / Revenue 10.66x
FIVN carries the larger enterprise value at $3.06B against $812.63M; FIVN trades on the lower EV / Revenue multiple (2.66x vs 10.66x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Five9, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
CytomX Therapeutics, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.03x
0.17x
Net debt / EBITDA
Leverage against operating earnings
4.21x
-0.27x
Cash and equivalents
Liquid reserves on the balance sheet
$232.08M
$12.67M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
RingCentral, Inc.
FIVN vs RNG
8X8 INC /DE/
FIVN vs EGHT
Zoom Communications, Inc.
FIVN vs ZM
PEGASYSTEMS INC
FIVN vs PEGA
VERINT SYSTEMS INC
FIVN vs VRNT
IDEAYA Biosciences, Inc.
FIVN vs IDYA
EXELIXIS, INC.
FIVN vs EXEL
GILEAD SCIENCES, INC.
FIVN vs GILD
AMGEN INC
FIVN vs AMGN
AbbVie Inc.
FIVN vs ABBV
BRISTOL MYERS SQUIBB CO
FIVN vs BMY
$807.25M
$16.89M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
